Itb-med Llc

This early-stage trial tests the safety of siplizumab, a drug that may calm the immune system, in 48 adults newly diagnosed with ALS. Researchers will monitor side effects and how the drug moves through the body. The goal is to see if it is safe enough for larger studies.

This phase 2 study tests whether a drug called TCD601 (siplizumab), combined with donor bone marrow cells and mild chemotherapy, can train the immune system to accept a new kidney without needing lifelong anti-rejection drugs. The trial involves 18 adults receiving a kidney from …

This study tested a new drug called TCD601 (siplizumab) in 33 kidney transplant patients to see if it could safely prevent organ rejection. The drug was compared to a standard treatment (ATG). The trial was stopped early, so we have limited information, but the goal was to find a…

This study tested a drug called siplizumab combined with donor bone marrow cells to help kidney transplant patients potentially stop taking anti-rejection drugs long-term. Only 4 people took part before the study was ended early. The goal was to find the best dose to safely allow…